Cytokine Gene Therapy of Cancer Using Gene Gun Technology: Superior Antitumor Activity of Interleukin-12
- 20 July 1997
- journal article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 8 (11) , 1303-1311
- https://doi.org/10.1089/hum.1997.8.11-1303
Abstract
We compared the antitumor effect of several transgene expression plasmids encoding specific cytokines, including interleukin-2 (IL-2), IL-4, IL-6, IL-12, interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), and granulocyte-macrophage colony-stimulating factor (GM-CSF), following gene gun-mediated DNA delivery into the epidermis overlying an established intradermal murine tumor. IL-12 gene therapy was much more effective than treatment with any other tested cytokine gene for induction of tumor regression. Strong activation of antitumor immunity in response to IL-12 gene therapy was evidenced by an augmented CD8+ T cell-mediated cytolytic activity in the draining lymph nodes of tumor-bearing mice. Furthermore, following the IL-12 gene therapy protocol, test mice were able to eradicate not only the treated but also the untreated solid tumors at distant sites. This systemic antitumor effect of IL-12 gene therapy was not associated with visible signs of toxicity or significantly elevated systemic levels of IFN-gamma. These results show that gene gun-mediated in vivo delivery of IL-12 cDNA clearly distinguishes itself from the other cytokine gene therapy approaches tested in parallel, suggesting that this delivery system may be employed as an efficient model for comparative studies of in vivo cytokine gene therapy. The results also suggest that the current IL-12 gene therapy strategy may provide a safer alternative to IL-12 protein therapy for clinical treatment of cancers.Keywords
This publication has 32 references indexed in Scilit:
- After Initial Setback, IL-12 Regaining PopularityJNCI Journal of the National Cancer Institute, 1996
- Efficacy of tnf-α gene-transduced tumor cells in treatment of establishedin vivo tumorInternational Journal of Cancer, 1995
- Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cellsInternational Immunology, 1995
- ScienceScopeScience, 1995
- Role of Interferon-γ in Mediating the Antitumor Efficacy of Interleukin-12Journal of Immunotherapy, 1995
- FAILURE OF ANTI-T CELL MONOCLONAL ANTIBODIES TO PREVENT ACUTE TUMOR ALLOGRAFT REJECTION IS ASSOCIATED WITH THEIR INABILITY TO DEPLETE OR INACTIVATE T CELLS AT THE SITE OF REJECTION1Transplantation, 1994
- Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?Immunology Today, 1994
- T Cell Recognition of Human Tumors: Implications for Molecular Immunotherapy of CancerClinical Immunology and Immunopathology, 1993
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987